Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Boukhaled GM, et al. Among authors: lau scm. Nat Immunol. 2022 Aug;23(8):1273-1283. doi: 10.1038/s41590-022-01262-7. Epub 2022 Jul 14. Nat Immunol. 2022. PMID: 35835962
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Hwang DM, Albaqer T, Santiago RC, Weiss J, Tanguay J, Cabanero M, Leung Y, Pal P, Khan Z, Lau SCM, Sacher A, Torlakovic E, Cheung C, Tsao MS. Hwang DM, et al. Among authors: lau scm. J Thorac Oncol. 2021 Sep;16(9):1490-1500. doi: 10.1016/j.jtho.2021.03.028. Epub 2021 Apr 26. J Thorac Oncol. 2021. PMID: 33915250 Free article.
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.
Lau SCM, Ryan M, Weiss J, Fares AF, Garcia M, Schmid S, Kuang S, Kelly D, Tsao MS, Bradbury PA, Cho BCJ, Sun A, Raman S, Hope A, Giuliani M, Lok BH, Bezjak A, Liu G, Leighl NB, Shepherd FA, Sacher AG. Lau SCM, et al. JTO Clin Res Rep. 2021 Nov 2;2(12):100251. doi: 10.1016/j.jtocrr.2021.100251. eCollection 2021 Dec. JTO Clin Res Rep. 2021. PMID: 34917991 Free PMC article.
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM, Rabindranath M, Weiss J, Li JJN, Fung AS, Mullen D, Alshamlan N, Ruff HM, Tong LCB, Pal P, Cabanero MR, Hsu YR, Sacher AG, Shepherd FA, Liu G, Bradbury PA, Yasufuku K, Czarnecka-Kujawa K, Mi Ko H, Tsao MS, Leighl NB, Schwock J. Lau SCM, et al. Lung Cancer. 2022 Sep;171:42-46. doi: 10.1016/j.lungcan.2022.07.018. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35907387 Review.
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
Lau SCM, Perdrizet K, Fung AS, Mata DGMM, Weiss J, Holzapfel N, Liu G, Bradbury PA, Shepherd FA, Sacher AG, Feilotter H, Sheffield B, Hwang D, Tsao MS, Cheng S, Cheema P, Leighl NB. Lau SCM, et al. JTO Clin Res Rep. 2023 Aug 19;4(10):100562. doi: 10.1016/j.jtocrr.2023.100562. eCollection 2023 Oct. JTO Clin Res Rep. 2023. PMID: 37744308 Free PMC article.
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.
Fares AF, Lok BH, Zhang T, Cabanero M, Lau SCM, Stockley T, Patel D, Bradbury PA, Sacher A, Yasufuku K, Morash BA, Sabatini PJB, Nguyen LN, Leighl NB, Tsao MS, Shepherd FA, Liu G, Martins-Filho SN, Pal P. Fares AF, et al. Among authors: lau scm. Lung Cancer. 2020 Aug;146:350-354. doi: 10.1016/j.lungcan.2020.06.005. Epub 2020 Jun 9. Lung Cancer. 2020. PMID: 32546380 No abstract available.
27 results